Investors Overview

Corporate Profile

Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 trials that is being developed for the treatment of Demodex blepharitis.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

  • Report of unscheduled material events or corporate event

  • 3

    Initial filing by director officer or owner of more than ten percent.

  • 4

    Statement of changes in beneficial ownership of securities